Super Session 6 - Oncology Diagnostics 2020 – new tools for precision oncology
Thursday, September 15, 2016
•
S7
•
8:30 AM
>
9:30 AM
•
Super Session 6 - Oncology Diagnostics 2020 – new tools for precision oncology
•
Plenary Room A3
Hosted by Oslo Cluster Cluster, co-hosted by Roche
Precise diagnostics are extremely relevant for guiding treatment decisions in all stages of a patient’s cancer disease – from early diagnosis to therapy selection and treatment monitoring to early detection of recurrence. Novel diagnostics are developed and tested for various types of cancers and building on new technologies including -omics, liquid biopsies, single cell technologies, nanotechnology, real-time monitoring supported by digital / ICT solutions and remote monitoring. Recent developments and emerging trends in cancer diagnostics are presented and discussed in this forward-looking, inspirational session. Spotlight is on Nordic examples and visionary solutions aiming to optimize clinical decision making.
Moderator:
Dr. Patrick Larcier, Vice-President Drug Development & Vigilance Operations, Voisin Consulting Life Sciences
Speakers:
Dr. Dirk Heckermann, PHC Partnering Director, Roche
Prof. Carl Borrebaeck, Centre Director CREATE Health, Lund University
Dr. Lao Saal, CEO, Saga Diagnostics
Ms. Kaisa Helminen, CEO, Fimmic
Ms. Gitte Pedersen, CEO, Genomic Expression
|